Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Presenter: Federico Cappuzzo- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Presenter: Federico Cappuzzo- Abstract
Loading...
-
+
P2.14 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- 17:15 - 19:15
- 8/08/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
-
+
P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Presenter: Lorenza Landi- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
Session Moderator
12:52 - 13:00 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
Session Moderator
12:52 - 13:00 | Presenter: Jii Bum (Joy) Lee
- Abstract
Loading... -
+
MA13.01 - Session Introduction
12:00 - 12:01 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
MA13.02 - Session Introduction
12:01 - 12:02 | Presenter: Jii Bum (Joy) Lee
- Abstract
Loading... -
+
MA13.03 - Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
12:02 - 12:07 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading... -
+
MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
12:07 - 12:12 | Presenter: Yun Fan
- Abstract
Loading... -
+
MA13.05 - TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
12:12 - 12:17 | Presenter: Igor Odintsov
- Abstract
Loading... -
+
MA13.06 - Discussant
12:17 - 12:27 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
MA13.07 - TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
12:27 - 12:32 | Presenter: Benjamin Levy
- Abstract
Loading... -
+
MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
12:32 - 12:37 | Presenter: Jonathan Riess
- Abstract
Loading... -
+
MA13.09 - Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer
12:37 - 12:42 | Presenter: Sagar Rakshit
- Abstract
Loading... -
+
MA13.10 - Discussant
12:42 - 12:52 | Presenter: Paolo Bironzo
- Abstract
Loading... -
+
MA13.11 - Live Q&A
12:52 - 13:00
- Abstract
Loading...
